Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Sartorius

BATS-CHIXE:SRT3D
Snowflake Description

Reasonable growth potential with acceptable track record.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
SRT3D
BATS-CHIXE
€15B
Market Cap
  1. Home
  2. GB
  3. Healthcare
Company description

Sartorius Aktiengesellschaft supplies pharmaceutical and laboratory equipment worldwide. The last earnings update was 62 days ago. More info.


Add to Portfolio Compare Print
SRT3D Share Price and Events
7 Day Returns
-3.8%
BATS-CHIXE:SRT3D
-1.2%
GB Medical Equipment
0.1%
GB Market
1 Year Returns
33.9%
BATS-CHIXE:SRT3D
-0.3%
GB Medical Equipment
-23.6%
GB Market
SRT3D Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Sartorius (SRT3D) -3.8% 1% 10.9% 33.9% 170.1% 570.7%
GB Medical Equipment -1.2% -12% -19.1% -0.3% -2.3% 20.9%
GB Market 0.1% -15.5% -27% -23.6% -24.3% -23.5%
1 Year Return vs Industry and Market
  • SRT3D outperformed the Medical Equipment industry which returned -0.3% over the past year.
  • SRT3D outperformed the Market in United Kingdom of Great Britain and Northern Ireland which returned -23.6% over the past year.
Price Volatility
SRT3D
Industry
5yr Volatility vs Market

SRT3D Value

 Is Sartorius undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Sartorius to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Sartorius.

BATS-CHIXE:SRT3D Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 14 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 5.4%
Perpetual Growth Rate 10-Year GB Government Bond Rate 0.5%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for BATS-CHIXE:SRT3D
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year GB Govt Bond Rate 0.5%
Equity Risk Premium S&P Global 5.4%
Medical Equipment Unlevered Beta Simply Wall St/ S&P Global 0.81
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.808 (1 + (1- 30%) (7.25%))
0.899
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.9
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.53% + (0.899 * 5.44%)
5.42%

Discounted Cash Flow Calculation for BATS-CHIXE:SRT3D using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Sartorius is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

BATS-CHIXE:SRT3D DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (EUR, Millions) Source Present Value
Discounted (@ 5.42%)
2020 166.18 Analyst x6 157.64
2021 245.96 Analyst x7 221.32
2022 276.73 Analyst x3 236.22
2023 298.17 Est @ 7.75% 241.44
2024 314.82 Est @ 5.58% 241.81
2025 327.62 Est @ 4.07% 238.71
2026 337.47 Est @ 3.01% 233.25
2027 345.10 Est @ 2.26% 226.26
2028 351.12 Est @ 1.74% 218.38
2029 355.96 Est @ 1.38% 210.01
Present value of next 10 years cash flows €2,225.00
BATS-CHIXE:SRT3D DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= €355.96 × (1 + 0.53%) ÷ (5.42% – 0.53%)
€7,320.34
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= €7,320.34 ÷ (1 + 5.42%)10
€4,318.85
BATS-CHIXE:SRT3D Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= €2,225.00 + €4,318.85
€6,543.85
Equity Value per Share
(EUR)
= Total value / Shares Outstanding
= €6,543.85 / 68.39
€95.69
BATS-CHIXE:SRT3D Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in BATS-CHIXE:SRT3D represents 1.04537x of XTRA:SRT
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
1.04537x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (EUR) x Listing Adjustment Factor
= € 95.69 x 1.04537
€100.03
Value per share (EUR) From above. €100.03
Current discount Discount to share price of €214.30
= -1 x (€214.30 - €100.03) / €100.03
-114.2%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of Sartorius is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Sartorius's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Sartorius's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
BATS-CHIXE:SRT3D PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in EUR €2.29
XTRA:SRT Share Price ** XTRA (2020-04-07) in EUR €205
United Kingdom of Great Britain and Northern Ireland Medical Equipment Industry PE Ratio Median Figure of 11 Publicly-Listed Medical Equipment Companies 25.55x
United Kingdom of Great Britain and Northern Ireland Market PE Ratio Median Figure of 748 Publicly-Listed Companies 12.61x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Sartorius.

BATS-CHIXE:SRT3D PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= XTRA:SRT Share Price ÷ EPS (both in EUR)

= 205 ÷ 2.29

89.44x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Sartorius is overvalued based on earnings compared to the GB Medical Equipment industry average.
  • Sartorius is overvalued based on earnings compared to the United Kingdom of Great Britain and Northern Ireland market.
Price based on expected Growth
Does Sartorius's expected growth come at a high price?
Raw Data
BATS-CHIXE:SRT3D PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 89.44x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 14 Analysts
16.9%per year
United Kingdom of Great Britain and Northern Ireland Medical Equipment Industry PEG Ratio Median Figure of 8 Publicly-Listed Medical Equipment Companies 2x
United Kingdom of Great Britain and Northern Ireland Market PEG Ratio Median Figure of 517 Publicly-Listed Companies 0.99x

*Line of best fit is calculated by linear regression .

BATS-CHIXE:SRT3D PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 89.44x ÷ 16.9%

5.31x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Sartorius is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on Sartorius's assets?
Raw Data
BATS-CHIXE:SRT3D PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in EUR €11.85
XTRA:SRT Share Price * XTRA (2020-04-07) in EUR €205
United Kingdom of Great Britain and Northern Ireland Medical Equipment Industry PB Ratio Median Figure of 20 Publicly-Listed Medical Equipment Companies 2.83x
United Kingdom of Great Britain and Northern Ireland Market PB Ratio Median Figure of 1,323 Publicly-Listed Companies 1.11x
BATS-CHIXE:SRT3D PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= XTRA:SRT Share Price ÷ Book Value per Share (both in EUR)

= 205 ÷ 11.85

17.3x

* Primary Listing of Sartorius.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Sartorius is overvalued based on assets compared to the GB Medical Equipment industry average.
X
Value checks
We assess Sartorius's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Medical Equipment industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Medical Equipment industry average (and greater than 0)? (1 check)
  5. Sartorius has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

SRT3D Future Performance

 How is Sartorius expected to perform in the next 1 to 3 years based on estimates from 14 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
16.9%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Sartorius expected to grow at an attractive rate?
  • Sartorius's earnings growth is expected to exceed the low risk savings rate of 0.5%.
Growth vs Market Checks
  • Sartorius's earnings growth is expected to exceed the United Kingdom of Great Britain and Northern Ireland market average.
  • Sartorius's revenue growth is expected to exceed the United Kingdom of Great Britain and Northern Ireland market average.
Annual Growth Rates Comparison
Raw Data
BATS-CHIXE:SRT3D Future Growth Rates Data Sources
Data Point Source Value (per year)
BATS-CHIXE:SRT3D Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 14 Analysts 16.9%
BATS-CHIXE:SRT3D Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 14 Analysts 10.9%
United Kingdom of Great Britain and Northern Ireland Medical Equipment Industry Earnings Growth Rate Market Cap Weighted Average 21.1%
United Kingdom of Great Britain and Northern Ireland Medical Equipment Industry Revenue Growth Rate Market Cap Weighted Average 6.2%
United Kingdom of Great Britain and Northern Ireland Market Earnings Growth Rate Market Cap Weighted Average 15.5%
United Kingdom of Great Britain and Northern Ireland Market Revenue Growth Rate Market Cap Weighted Average 2.5%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
BATS-CHIXE:SRT3D Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 14 Analyst Estimates (S&P Global) See Below
All numbers in EUR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
BATS-CHIXE:SRT3D Future Estimates Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 3,280 750 412 4
2023-12-31 2,890 688 351 6
2022-12-31 2,666 526 304 12
2021-12-31 2,413 456 264 14
2020-12-31 2,142 362 222 14
2020-04-07
BATS-CHIXE:SRT3D Past Financials Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income *
2019-12-31 1,827 377 157
2019-09-30 1,768 337 171
2019-06-30 1,702 318 166
2019-03-31 1,637 312 153
2018-12-31 1,566 245 141
2018-09-30 1,518 245 138
2018-06-30 1,460 244 126
2018-03-31 1,426 223 115
2017-12-31 1,405 207 115
2017-09-30 1,376 185 91
2017-06-30 1,377 182 96
2017-03-31 1,341 173 105

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Sartorius's earnings are expected to grow by 16.9% yearly, however this is not considered high growth (20% yearly).
  • Sartorius's revenue is expected to grow by 10.9% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
BATS-CHIXE:SRT3D Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 14 Analyst Estimates (S&P Global) See Below

All data from Sartorius Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BATS-CHIXE:SRT3D Future Estimates Data
Date (Data in EUR Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31 6.03 6.03 6.03 1.00
2023-12-31 5.28 5.28 5.28 1.00
2022-12-31 4.40 4.59 4.20 2.00
2021-12-31 3.78 3.89 3.67 2.00
2020-12-31 3.07 3.32 2.82 2.00
2020-04-07
BATS-CHIXE:SRT3D Past Financials Data
Date (Data in EUR Millions) EPS *
2019-12-31 2.29
2019-09-30
2019-06-30
2019-03-31
2018-12-31 2.07
2018-09-30
2018-06-30
2018-03-31
2017-12-31 1.68
2017-09-30
2017-06-30
2017-03-31

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Sartorius is expected to efficiently use shareholders’ funds in the future (Return on Equity greater than 20%).
X
Future performance checks
We assess Sartorius's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United Kingdom of Great Britain and Northern Ireland market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United Kingdom of Great Britain and Northern Ireland market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Sartorius has a total score of 4/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

SRT3D Past Performance

  How has Sartorius performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Sartorius's growth in the last year to its industry (Medical Equipment).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Sartorius has delivered over 20% year on year earnings growth in the past 5 years.
  • Sartorius's 1-year earnings growth is less than its 5-year average (10.9% vs 20.6%)
  • Sartorius's earnings growth has exceeded the GB Medical Equipment industry average in the past year (10.9% vs -9.5%).
Earnings and Revenue History
Sartorius's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Sartorius Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BATS-CHIXE:SRT3D Past Revenue, Cash Flow and Net Income Data
Date (Data in EUR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 1,826.97 156.75 478.15 95.59
2019-09-30 1,768.13 171.24 464.39 84.80
2019-06-30 1,702.33 166.34 451.69 82.40
2019-03-31 1,636.83 152.54 441.19 79.20
2018-12-31 1,566.03 141.34 425.19 78.20
2018-09-30 1,517.87 137.73 415.72 76.38
2018-06-30 1,460.47 125.93 400.82 74.98
2018-03-31 1,426.37 114.73 390.42 73.88
2017-12-31 1,404.57 114.73 381.22 68.78
2017-09-30 1,375.60 91.03 371.05 68.62
2017-06-30 1,377.40 95.63 362.05 64.72
2017-03-31 1,341.50 105.23 345.45 61.52
2016-12-31 1,300.30 102.93 332.55 59.42
2016-09-30 1,249.55 98.86 321.96 58.51
2016-06-30 1,204.85 100.86 310.76 56.81
2016-03-31 1,158.55 95.86 301.76 52.81
2015-12-31 1,114.75 85.46 292.86 52.51
2015-09-30 1,075.97 76.46 284.50 44.36
2015-06-30 1,003.47 60.76 275.40 43.56
2015-03-31 946.17 47.39 266.93 51.11
2014-12-31 891.17 43.96 260.20 43.56
2014-09-30 779.76 42.89 227.81 45.51
2014-06-30 773.26 41.99 229.01 46.81
2014-03-31 780.36 45.59 231.71 47.91
2013-12-31 791.56 47.89 232.91 47.71
2013-09-30 863.61 51.01 257.11 52.12
2013-06-30 864.91 53.51 254.11 50.92

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Sartorius has efficiently used shareholders’ funds last year (Return on Equity greater than 20%).
  • Sartorius used its assets less efficiently than the GB Medical Equipment industry average last year based on Return on Assets.
  • Sartorius's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess Sartorius's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Medical Equipment industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Sartorius has a total score of 3/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

SRT3D Health

 How is Sartorius's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Sartorius's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Sartorius is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Sartorius's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of Sartorius's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is not covered by short term assets, assets are 0.9x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Sartorius Company Filings, last reported 3 months ago.

BATS-CHIXE:SRT3D Past Debt and Equity Data
Date (Data in EUR Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 1,081.21 991.09 65.88
2019-09-30 1,094.90 1,009.50 85.20
2019-06-30 1,020.30 1,021.50 71.30
2019-03-31 979.00 954.50 68.50
2018-12-31 973.39 985.85 67.34
2018-09-30 894.30 1,008.50 117.90
2018-06-30 845.20 986.90 74.70
2018-03-31 833.00 949.60 107.10
2017-12-31 806.56 934.40 74.68
2017-09-30 773.90 955.10 100.30
2017-06-30 747.20 971.20 99.80
2017-03-31 780.40 917.20 166.30
2016-12-31 736.80 526.00 72.07
2016-09-30 691.20 539.30 78.80
2016-06-30 654.10 538.20 91.80
2016-03-31 665.70 390.60 71.00
2015-12-31 644.75 374.99 61.08
2015-09-30 625.70 347.20 56.80
2015-06-30 588.60 331.90 61.10
2015-03-31 574.60 320.40 85.30
2014-12-31 497.66 370.98 52.19
2014-09-30 483.90 411.50 57.20
2014-06-30 453.10 411.20 50.70
2014-03-31 463.60 390.60 58.20
2013-12-31 450.25 382.55 63.42
2013-09-30 434.10 366.10 41.40
2013-06-30 420.30 379.00 35.90
  • Sartorius's level of debt (91.7%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (74.3% vs 91.7% today).
  • Debt is well covered by operating cash flow (38.1%, greater than 20% of total debt).
  • Interest payments on debt are well covered by earnings (EBIT is 25.3x coverage).
X
Financial health checks
We assess Sartorius's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Sartorius has a total score of 3/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

SRT3D Dividends

 What is Sartorius's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0.34%
Current annual income from Sartorius dividends. Estimated to be 0.55% next year.
If you bought €2,000 of Sartorius shares you are expected to receive €7 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Sartorius's pays a lower dividend yield than the bottom 25% of dividend payers in United Kingdom of Great Britain and Northern Ireland (2.59%).
  • Sartorius's dividend is below the markets top 25% of dividend payers in United Kingdom of Great Britain and Northern Ireland (7.08%).
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
BATS-CHIXE:SRT3D Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 14 Analyst Estimates (S&P Global) See Below
United Kingdom of Great Britain and Northern Ireland Medical Equipment Industry Average Dividend Yield Market Cap Weighted Average of 5 Stocks 2.2%
United Kingdom of Great Britain and Northern Ireland Market Average Dividend Yield Market Cap Weighted Average of 588 Stocks 5.6%
United Kingdom of Great Britain and Northern Ireland Minimum Threshold Dividend Yield 10th Percentile 1.3%
United Kingdom of Great Britain and Northern Ireland Bottom 25% Dividend Yield 25th Percentile 2.6%
United Kingdom of Great Britain and Northern Ireland Top 25% Dividend Yield 75th Percentile 7.1%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

BATS-CHIXE:SRT3D Future Dividends Estimate Data
Date (Data in €) Dividend per Share (annual) Avg. No. Analysts
2024-12-31 1.63 1.00
2023-12-31 1.45 1.00
2022-12-31 1.14 2.00
2021-12-31 1.00 2.00
2020-12-31 0.84 2.00
2020-04-07
BATS-CHIXE:SRT3D Past Annualized Dividends Data
Date (Data in €) Dividend per share (annual) Avg. Yield (%)
2020-02-05 0.700 0.357
2019-03-28 0.610 0.378
2018-04-05 0.500 0.432
2017-04-06 0.450 0.540
2016-04-08 0.375 0.534
2015-03-02 0.265 0.539
2014-04-10 0.250 1.009
2013-02-18 0.235 1.076
2012-04-19 0.200 1.439
2011-02-22 0.150 1.813
2011-02-09 0.150 2.022
2010-03-01 0.100 1.844

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Sartorius is not paying a notable dividend for United Kingdom of Great Britain and Northern Ireland, therefore no need to check if the payments are stable.
  • Sartorius is not paying a notable dividend for United Kingdom of Great Britain and Northern Ireland, therefore no need to check if the payments are increasing.
Current Payout to shareholders
What portion of Sartorius's earnings are paid to the shareholders as a dividend.
  • No need to calculate the sustainability of Sartorius's dividends as it is not paying a notable one for United Kingdom of Great Britain and Northern Ireland.
Future Payout to shareholders
  • No need to calculate the sustainability of Sartorius's dividends in 3 years as they are not expected to pay a notable one for United Kingdom of Great Britain and Northern Ireland.
X
Income/ dividend checks
We assess Sartorius's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.3%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Sartorius afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Sartorius has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

SRT3D Management

 What is the CEO of Sartorius's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Joachim Kreuzburg
COMPENSATION €2,061,000
AGE 54
TENURE AS CEO 16.9 years
CEO Bio

Dr. rer. pol. Joachim Kreuzburg serves as the Chairman and Chief Executive Officer at Sartorius Stedim Biotech GmbH. Dr. rer. pol. Kreuzburg has been the Chairman of Executive Board at Sartorius Aktiengesellschaft (Alternative Name: Sartorius AG) since November 11, 2005 and its Group Chief Executive Officer since May 1, 2003. Dr. rer. pol. Kreuzburg has been a Member of Executive Board at Sartorius Aktiengesellschaft since November 11, 2002 and served as its “Sprecher” (Spokesman) from May 1, 2003 to November 10, 2005. He serves as the Chairman and Chief Executive Officer at Sartorius Stedim Biotech SA. He served as the Chief Financial Officer of Sartorius Aktiengesellschaft since May 1, 2003. He served as an Executive for Labor Relations at Sartorius Aktiengesellschaft since September 2009. Dr. rer. pol. Kreuzburg served as the Chairman and Chief Executive Officer of Biotechnology Division at Sartorius Aktiengesellschaft since June 2007 and also served as its President of Biotechnology Division. He served as a Vice President of Treasury and Investor Relations at Sartorius Aktiengesellschaft. He serves as a Director of Sartorius Omnimark Instrument Corporation. He serves as Member of the Board of Directors of IntelliCyt Corporation. He served as Member of the Board of Directors of kSep Holdings, Inc. He served as Member of the Board of Directors of ViroCyt, Inc. He served as Member of the Advisory Board (Beirat) of Hameln Group GmbH, Germany. Chairman of the Advisory Board (Beirat) of Otto Bock Holding GmbH & Co. KG, Germany. He serves as Managing Director of Sartorius Lab Holding GmbH; Managing Director of Sartorius Corporate Administration GmbH; Managing Director of Sartorius Weighing Technology GmbH; Managing Director of SWT Treuhand GmbH; Managing Director of SI Weende-Verwaltungs-GmbH Managing Director of SI Grone 1 -Verwaltungs-GmbH. He served as President of VL Finance S.A.S. He served as Member of Advisory Board at Norddeutsche Landesbank Girozentrale. He has been Director of Sartorius Stedim Biotech S.A. since June 29, 2007. He serves as a Member of Supervisory Board at Carl Zeiss AG. He served as a Director of Biotechnology Division at Sartorius Aktiengesellschaft. He was Research associate at the Institute for Solar Energy Research in Hamelin, Germany from 1992 to 1995. He was Research associate at the Faculty of Economics and Management at the University of Hanover, Germany from 1995to 1999. He was the Executive Board: Vice President, Finances and Investor Relations at Sartorius AG, Goettingen, Germany since May 1, 1999. He is Member of the Executive Board of Sartorius AG, Goettingen, Germany Spokesman (Sprecher) of the Executive Board of Sartorius AG, Goettingen, Germany since November 11, 2002 and May 1, 2003 to November 10, 2005 Respectively. He holds a Doctorate in Economics. Dr. rer. pol. Kreuzburg holds a Degree from Mechanical Engineering from the University of Hannover, Germany.

CEO Compensation
  • Joachim's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Joachim's remuneration is lower than average for companies of similar size in United Kingdom of Great Britain and Northern Ireland.
Management Team Tenure

Average tenure and age of the Sartorius management team in years:

2.3
Average Tenure
50
Average Age
  • The tenure for the Sartorius management team is about average.
Management Team

Joachim Kreuzburg

TITLE
Chairman of Executive Board & CEO
COMPENSATION
€2M
AGE
54
TENURE
16.9 yrs

Rainer Lehmann

TITLE
CFO, Member of Executive Board and Head of Finance
COMPENSATION
€922K
AGE
43
TENURE
2.3 yrs

Gerry Mackay

TITLE
Head of Lab Products & Services Division and Member of Executive Board
COMPENSATION
€991K
AGE
57
TENURE
1.3 yrs

René Fáber

TITLE
Head of Bioprocess Solutions Division & Member of Executive Board
COMPENSATION
€861K
AGE
44
TENURE
1.3 yrs

Petra Kirchhoff

TITLE
Head of Corporate Communications & Investor Relations and Member of Supervisory Board
COMPENSATION
€56K
AGE
50
TENURE
3.3 yrs

Manfred Werner

TITLE
Senior Vice President of Administration Organization & Auditing

Mei Wang

TITLE
Head of Production - China

Patricia Spannagel

TITLE
Head of Quality Assurance - Mechatronics Division Goettingen

Rashid Maqbool

TITLE
Head of Production & Certification Department - Denver USA

Manohar Kuppusami

TITLE
Head of Production Department - India
Board of Directors Tenure

Average tenure and age of the Sartorius board of directors in years:

8
Average Tenure
62
Average Age
  • The tenure for the Sartorius board of directors is about average.
Board of Directors

Lothar Kappich

TITLE
Chairman of Supervisory Board
COMPENSATION
€246K
AGE
62
TENURE
2.8 yrs

Manfred Zaffke

TITLE
Vice Chairman of the Supervisory Board
COMPENSATION
€137K
AGE
62
TENURE
6.1 yrs

Petra Kirchhoff

TITLE
Head of Corporate Communications & Investor Relations and Member of Supervisory Board
COMPENSATION
€56K
AGE
50

Klaus Trützschler

TITLE
Member of Supervisory Board
COMPENSATION
€107K
AGE
71
TENURE
8.4 yrs

Uwe Bretthauer

TITLE
Member of Supervisory Board
COMPENSATION
€92K

Annette Becker

TITLE
Member of the Supervisory Board
COMPENSATION
€56K
AGE
55

Michael Dohrmann

TITLE
Member of the Supervisory Board
COMPENSATION
€56K
AGE
63
TENURE
13.3 yrs

Thomas Scheper

TITLE
Member of the Supervisory Board
COMPENSATION
€45K
AGE
63
TENURE
8 yrs

Karoline Kleinschmidt

TITLE
Member of the Supervisory Board
COMPENSATION
€56K
AGE
54
TENURE
8 yrs

Daniela Favoccia

TITLE
Member of Supervisory Board
COMPENSATION
€53K
AGE
55
TENURE
3 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Sartorius's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Sartorius has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

SRT3D News

Simply Wall St News

SRT3D Company Info

Description

Sartorius Aktiengesellschaft supplies pharmaceutical and laboratory equipment worldwide. It operates in two divisions, Bioprocess Solutions, and Lab Products & Services. The company offers live cell analysis system, and cell analysis reagents and consumables; cell culture media, including antibody and recombinant protein, viral vaccines, and regenerative medicine media, as well as general media and downstream buffers; and multi-parallel, single-use, benchtop, stainless steel, microbial, and cell culture bioreactors, as well as cell culture expansion systems and software applications for bioreactors. It also provides lab filtration and purification devices; sterile and virus filtration, crossflow filtration, harvesting, prefiltration, membrane chromatography, air/gas filtration, and integrity testing devices; and liquid storage and shipping, freeze and thaw, mixing, proven integrity, transferring and sampling, connecting and disconnecting, and final filling management products. In addition, the company offers process control and data analytics products, such as process analyzers, automation modules, and data analytics and chemometrics; and microbiology products, and lab water purification systems. Further, it provides lab balances, mass comparators and metrology, moisture analyzers, specialty weighing solutions, weighing accessories, weights/weight sets, paint mixing solutions, and OEM weigh cells; and OEM membrane and device, pipetting and dispensing, and connectivity solutions. Additionally, the company offers bioprocess development engineering, protein expression system, media and process, testing, instrument, and validation services. It serves the life science research, biopharmaceutical manufacturing, quality control and testing, cannabis testing, food and beverage, environmental, and paint mixing industries. The company was founded in 1870 and is headquartered in Göttingen, Germany.

Details
Name: Sartorius Aktiengesellschaft
SRT3D
Exchange: BATS-CHIXE
Founded: 1870
€14,696,322,162
68,388,292
Website: http://www.sartorius.com
Address: Sartorius Aktiengesellschaft
Otto-Brenner-Strasse 20,
Göttingen,
Lower Saxony, 37079,
Germany
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
XTRA SRT Ordinary Shares XETRA Trading Platform DE EUR 02. Jan 1992
OTCPK SART.F Ordinary Shares Pink Sheets LLC US USD 02. Jan 1992
DB SRT Ordinary Shares Deutsche Boerse AG DE EUR 02. Jan 1992
LSE 0NIQ Ordinary Shares London Stock Exchange GB EUR 02. Jan 1992
ETLX SRT Ordinary Shares Eurotlx IT EUR 02. Jan 1992
XTRA SRT3 Preference Shares XETRA Trading Platform DE EUR 02. Jan 1992
OTCPK SUVP.F Preference Shares Pink Sheets LLC US USD 02. Jan 1992
DB SRT3 Preference Shares Deutsche Boerse AG DE EUR 02. Jan 1992
LSE 0NIR Preference Shares London Stock Exchange GB EUR 02. Jan 1992
SWX SRT3 Preference Shares SIX Swiss Exchange CH CHF 02. Jan 1992
WBAG SRT3 Preference Shares Wiener Boerse AG AT EUR 02. Jan 1992
ETLX SRT3 Preference Shares Eurotlx IT EUR 02. Jan 1992
BATS-CHIXE SRT3D Preference Shares BATS 'Chi-X Europe' GB EUR 02. Jan 1992
Number of employees
Current staff
Staff numbers
9,016
Sartorius employees.
Industry
Health Care Equipment
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/07 20:48
End of day share price update: 2020/04/07 00:00
Last estimates confirmation: 2020/04/07
Last earnings filing: 2020/02/05
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.